The most effective natural Hypertension treatment
Click on a box to see what we consider
the most effective natural Hypertension treatment for you

WOMEN 39
AND UNDER		 MEN 39
AND UNDER		 WOMEN 40
AND UP		 MEN 40
AND UP
click here...click here...click here...click here...

What is Hypertension (high blood pressure)?

If your diastolic blood pressure (the pressure in the arteries when your heart is at rest/bottom number on the blood pressure test) is higher than 90 mmHg, you have high blood pressure. In more than 80 percent of all patients suffering from high blood pressure or hypertension the origin is unknown. If left untreated, hypertension increases the risk of developing, among other things, stroke, heart attack and atherosclerosis (hardening of the arteries).

As both inflammation and oxidation play a definitive role in the development of hypertension, specific natural nutritional nutrients (see below) are effective at lowering blood pressure and may prevent future complications.

Which natural ingredients can have an effect on high blood pressure?

Coenzyme Q10, vitamins C and D3, tocotrienols, fish oils (EPA/DHA), magnesium, calcium and many more.

What effects do these ingredients have?

  • Lower mild to moderate high blood pressure by 10% by reducing peripheral vascular resistance.
  • Reduce risk of cerebral hemorrhage.
  • Reduce risk of blood clots or embolisms.
  • Boost energy level.
  • Inhibit the oxidation of, among others, LDL (unhealthy) cholesterol.

For the reader with a deeper interest:

How do these ingredients work?

  • Treat and prevent vitamin and mineral deficiencies.
  • Lower peripheral vascular resistance.
  • Protect brain cells against temporary loss of brain function due to a transient ischemic attack (TIA).
  • Stabilize the capillary wall.
  • Improve myocardial contractibility.
  • Increase the production of ATP in the mitochondria (energy).
  • Inhibit platelet-aggregation.
  • Reduce oxidative stress.
  • Very potent antioxidant effect.
  • Anti-inflammatory effect.

The information above is based on more than 24,500 articles published in scientific journals and which are available at MEDLINE, the world's largest medical database. Below you will find a few of them listed:

References

  1. Agren JJ, Hanninen O, Julkunen A, et al. Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels. Eur J Clin Nutr. 1996;50:765-771.
  2. Alexander JW. Immunonutrition: the role of omega-3 fatty acids.Nutr 1998;14:627–33.
  3. Alleva R, Scararmucci A, Mantero F, et al. The protective role of ubiquinol-10 against formation of lipid hydroperoxides in human seminal fluid. Mol Aspects Med. 1997;18(Suppl):S221-8.
  4. Almallah YZ, El-Tahir A, Heys SD, et al. Distal procto-colitis and n-3 polyunsaturated fatty acids: the mechanism(s) of natural cytotoxicity inhibition. Eur J Clin Invest. 2000;30:58–65.
  5. Angerer P, Stork S, Kothny W, et al. Effect of marine omega-3 fatty acids on peripheral atherosclerosis in patients with coronary artery disease—a randomised 2 year intervention trial [abstract]. Eur Heart J. 2001;22(suppl):162.
  6. Appel LJ, Miller ER III, Seidler AJ, et al. Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med. 1993;153:1429–1438.
  7. Artuch R, Vilaseca MA, Moreno J, et al. Decreased serum ubiquinone-10 concentrations in phenylketonuria. Am J Clin Nutr 1999;70:892–5.
  8. Ascherio A, Rimm EB, Stampfer MJ, et al. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med. 1995;332:977–982.
  9. Bargossi AM, Grossi G, Fiorella PL, Gaddi A, Di Giulio R, Battino M. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction by HMG-CoA reductase inhibitors. Mol Aspects Med. 1994;15(Suppl):S187-S193.
  10. Billman GE, Hallaq H, Leaf A. Prevention of ischemia-induced ventricular fibrillation by omega 3 fatty acids. Proc Natl Acad Sci U S A. 1994;91:4427–4430.
  11. Bucher HC, Hengstler P, Schindler C, et al. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002;112:298-304.***
  12. Burke BE  & al. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J, 94(11): 1112-7   2002
  13. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;2:757–761.
  14. Chan A, Reichmann H, Kogel A, Beck A, Gold R. Metabolic changes in patients with mitochondrial myopathies and effects of Coenzym Q10 therapy. J Neurol. 1998;245:681-685.
  15. Childs MT, King IB, Knopp RH. Divergent lipoprotein responses to fish oils with various ratios of eicosapentaenoic acid and docosahexaenoic acid. Am J Clin Nutr. 1990;52:632-639.
  16. Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of Coenzym Q10 formulations in human subjects. Int J Vitam Nutr Res 1998;68:109–13.
  17. Cobiac L, Clifton PM, Abbey M, et al. Lipid, lipoprotein, and hemostatic effects of fish vs fish-oil n–3 fatty acids in mildly hyperlipidemic males. Am J Clin Nutr. 1991;53:1210–1216.
  18. Curb JD, Reed DM. Fish consumption and mortality from coronary heart disease [letter]. N Engl J Med. 1985;313:821–822.
  19. Danysz A, Oledzka K, Bukowska-Kiliszek M. Influence of Coenzym Q-10 on the hypotensive effects of enalapril and nitrendipine in spontaneously hypertensive rats. Pol J Pharmacol. 1994;46(5):457-461.
  20. Davidson MH, Maki KC, Kalkowski J, et al. Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. J Am Coll Nutr. 1997;16:236-243.
  21. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994;343:1454–1459.
  22. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate levels. Br J Clin Pharmacol. 1996;42(3):333-337.
  23. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354:447–455.
  24. Digiesi V, Cantini F, Bisi G, et al. Mechanism of action of Coenzym Q10 in essential hypertension. Curr Ther Res 1992;51:668–72.
  25. Dunstan DW, Burke V, Mori TA, et al. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. Diabetes Care 1997; 20:913–21.
  26. Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart. 2001;85:544–548.
  27. Dyerberg J. N-3 fatty acids and coronary artery disease: potentials and problems. Omega-3, Lipoproteins, and Atherosclerosis. 1996;27:251–258.
  28. Folkers K, Shizukuishi S, Takemura K, et al. Increase in levels of IgG in serum of patients treated with Coenzym Q10. Res Commun Pathol Pharmacol 1982;38:335–8.
  29. Folkers K, Wolaniuk J, Simonsen R, et al. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with Coenzym Q10. Proc Natl Acad Sci 1985;82:4513–6.
  30. Fujioka T, Sakamoto Y, Mimura G. Clinical study of cardiac arrhythmias using a 24-hour continuous electrocardiographic recorder (5th report)—antiarrhythmic action of Coenzym Q10 in diabetics. Tohoku J Exp Med 1983;141(suppl):453–63.
  31. Gaby AR. Coenzym Q10. In A Textbook of Natural Medicine, by Pizzorno JE, Murray MT. Seattle: Bastyr University Press, 1998, V:CoQ10–1–8. [review].
  32. Gaby AR. The role of Coenzym Q10 in clinical medicine: part II. Cardiovascular disease, hypertension, diabetes mellitus and infertility. Altern Med Rev 1996;1:168–75 [review].
  33. Gallai V, Sarchielli P, Trequattrini A, et al. Cytokine secretion and eicosanoid production in the peripheral blood mononuclear cells of MS patients undergoing dietary supplementation with n-3 polyunsaturated fatty acids. J Neuroimmunol. 1995;56:143–153.
  34. Geleijnse JM, Giltay EJ, Grobbee DE, et al. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002;20:1493-1499.
  35. Guallar E, Hennekens CH, Sacks FM, et al. A prospective study of plasma fish oil levels and incidence of myocardial infarction in U.S. male physicians. J Am Coll Cardiol. 1995;25:387–394.
  36. Harris WS, Zucker ML, Dujovne CA. Omega-3 fatty acids in type IV hyperlipidemia: fish oils vs methyl esters. Am J Clin Nutr 1987;45:858 [abstr].
  37. Harris WS. Dietary fish oil and blood lipids. Curr Opin Lipidol. 1996;7:3–7.
  38. Harris WS. N-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids. 1996;31:243–252.
  39. Harris WS. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65(5 suppl):S1645–S1654.
  40. Helland IB, Smith L, Saarem K, et al. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. Pediatrics. 2003;111:E39–E44.
  41. Hodgson JM & al , Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr, 56(11): 1137-42   2002
  42. Iso H, Rexrode KM, Stampfer MJ, et al. Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA. 2001;285:304–312.
  43. Jacobs MN, Santillo D, Johnston PA, et al. Organochlorine residues in fish oil dietary supplements: comparison with industrial grade oils. Chemosphere. 1998;37:1709-1721.
  44. Kaikkonen J, Nyyssonen K, Porkkala-Sarataho E, et al. Effect of oral Coenzym Q10 on the oxidation resistance of human VLDL + LDL fraction: absorption and antioxidative properties of oil and granule-based preparations. Free Radic Biol Med 1997;22:1195–202.
  45. Kamikawa T, et al. Effects of Coenzym Q10 on Exercise Tolerance in Chronic Stable Angina Pectoris. Am J Cardiol. Aug1985;56(4):247-51.
  46.  Khatta M, Alexander BS, Krichten CM, et al. The effect of Coenzym Q10 in patients with congestive heart failure. Ann Intern Med 2000;132:636–40.
  47.  Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985;312:1205–1209.
  48. H, Rexrode KM, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Hennekens CH, Willett WC. Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA. 2001; 285(3): 304-12.
  49. i S. Inhibition of leukocyte-endothelial interactions by oxidized omega-3 fatty acids: a novel mechanism for the anti-inflammatory effects of omega-3 fatty acids in fish oil. Redox Rep. 2002; 7(6): 369-78.
  50.  Kromhout D, Feskens EJ, Bowles CH. The protective effect of a small amount of fish on coronary heart disease mortality in an elderly population. Int J Epidemiol. 1995;24:340–345.
  51.  Landbo C, Almdal TP. [Interaction between warfarin and Coenzym Q10 (see comments)]. Ugeskr Laeger. 1998;160(22):3225-3227.
  52.  Langsjoen H, Langsjoen P, Langsjoen P, et al. Usefulness of Coenzym Q10 in clinical cardiology: a long-term study. Mol Aspects Med. 1994;15(Suppl):s165-75.
  53.  Langsjoen P, et al. Treatment of Essential Hypertension with Coenzym Q10. Mol Aspects Med. 1994;15(Suppl):S265-72.
  54.  Langsjoen PH, et al. A Six-year Clinical Study of Therapy of Cardiomyopathy with Coenzym Q10. Int J Tissue React. 1990;12(3):169-71.
  55.  Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation. 1994;90:2248–2257.
  56.  Miyake Y, Shouzu A, Nishikawa M, et al. Effect of treatment of 3-hydroxy-3-methylglutaryl Coenzym I reductase inhibitors on serum Coenzym Q10 in diabetic patients. Arzneimittelforschung 1999;49:324–9.
  57.  Møller T & al ,Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett, 341(3): 201-4   2003
  58.  Morisco C & al. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig, 71(8 Suppl): S134-6   1994
  59.  Morisco C, Trimarco B, Condorelli M. Effect of Coenzym Q10 in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig 1993;71:S134–6.
  60.  Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum Coenzym Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18 Suppl:S137-44.
  61.  Mortensen SA, Vadhanavikit S, Baandrup U, Folkers K. Long-term Coenzym Q10 therapy: a major advance in the management of resistant myocardial failure. Drug Exptl Clin Res 1985;11:581–93.
  62.  Mortensen SA. Perspectives on therapy of cardiovascular diseases with Coenzym Q10 (ubiquinone). Clin Invesigt 1993;71:S116–23 [review].
  63.  Murray MT, Pizzorno JE. Encyclopedia of Natural Medicine. 2nd ed. Rocklin, Calif: Prima Publishing; 1996.
  64.  Murray MT. Encyclopedia of Nutritional Supplements. Rocklin, Calif: Prima Publishing; 1996:296-308.
  65.  Niibori K, Yokoyama H, Crestanello JA, Whitman GJ. Acute administration of liposomal Coenzym Q10 increases myocardial tissue levels and improves tolerance to ischemia reperfusion injury. J Surg Res. 1998;79:141-145.
  66.  Oda T. Effect of Coenzym Q10 on Stress-induced Cardiac Dysfunction in Paediatric Patients with Mitral Valve Prolapse: A Study by Stress Echocardiography. Drugs Exp Clin Res. 1985;11(8):557-76.
  67.  Permanetter B, Rossy W, Klein G, et al. Ubiquinone (Coenzym Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J 1992;13:1528–33.
  68.  Portakal O, Inal-Erden M. Effects of pentoxifylline and Coenzym Q10 in hepatic ischemia/reperfusion injury. Clin Biochem. 1999;32:461-466.
  69.  Shils ME, Olson JA, Shike M, Ross AC. Modern Nutrition in Health and Disease. 9th ed. Baltimore, Md: Williams & Wilkins; 1999:90-92: 1377-1378.
  70.  Shinozawa S, Kawasaki H, Gomita Y. [Effect of biological membrane stabilizing drugs (Coenzym Q10, dextran sulfate and reduced glutathione) on adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice]. Gan To Kagaku Ryoho. 1996;23(1):93-98.
  71.  Sinatra ST. Coenzym Q10: A Vital Therapeutic Nutrient for the Heart with Special Application in Congestive Heart Failure. Conn Med. Nov1997;61(11):707-11.
  72.  Singh RB & al.Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther, 12(4): 347-53   1999
  73.  Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble Coenzym Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens. 1999;13(3):203-208.
  74.  Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind placebo-controlled trial of Coenzym Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 1998;12:347-353.
  75.  Soja AM, Mortensen SA. Treatment of chornic cardiac insufficiency with Coenzym Q10, results of meta-analysis in controlled clinical trials. Ugeskr Laeger 1997;159:7302–8.
  76.  Tanaka J, Tominaga R, Yoshitoshi M, et al. Coenzym Q10: the prophylactic effect on low cardiac output following cardiac valve replacement. Ann Thorac Surg 1982;33:145–51.
  77.  Thomas SR, Neuzil J, Stocker R. Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism for Coenzym Q in atherogenesis? Mol Aspects Med 1997;18:S85–103.
  78.  Tran MT, Mitchell TM, Kennedy DT, Giles JT. Role of Coenzym Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy. Jul2001;21(7):797-806.
  79.  Tsubaki K, et al. Investigation of the Preventive Effect of CoQ10 against the Side-effects of Anthracycline Antineoplastic Agents. Gan To Kagaku Ryoho. Jul1984;11(7):1420-27.
  80.  Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of Coenzym Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 1999;33:1549–52.
  81.  Weber C, Jakobsen TS, Mortensen SA, et al. Antioxidative effect of dietary Coenzym Q10 in human blood plasma. Int J Vitam Nutr Res 1994;64:311–5.
  82.  Zhou Q, Chan E. Accuracy of repeated blood sampling in rats: A new technique applied in pharmacokinetic/pharmacodynamic studies of the interaction between warfarin and Co-enzyme Q10. J Pharmacol Toxicol Methods. 1998;40(4):191-199.  & more.